MCID: MYL006
MIFTS: 66

Myeloid Leukemia malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Genetic diseases, Blood diseases

Aliases & Classifications for Myeloid Leukemia

Aliases & Descriptions for Myeloid Leukemia:

Name: Myeloid Leukemia 12 50 29 52 14 69
Myeloid Granulocytic Leukemia 12
Non-Lymphocytic Leukemia 12
Leukemia Myelogenous 12
Myeloid Leukaemia 14

Classifications:



Summaries for Myeloid Leukemia

Disease Ontology : 12 A leukemia that is located in myeloid tissue.

MalaCards based summary : Myeloid Leukemia, also known as myeloid granulocytic leukemia, is related to leukemia, acute myeloid and neurofibromatosis. An important gene associated with Myeloid Leukemia is RUNX1 (Runt Related Transcription Factor 1), and among its related pathways/superpathways are NF-kappaB Signaling and Pathways in cancer. The drugs Bosulif and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and cellular

Wikipedia : 71 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Acute Myeloid Leukemia, Flt3-Related
Acute Myeloid Leukemia, Kit-Related Npm1-Related Acute Myeloid Leukemia
Inherited Acute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 419)
id Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 33.4 FLT3 KIT MLF1 NPM1 NUP98 PTPN11
2 neurofibromatosis 30.3 FLT3 KIT NPM1
3 acute lymphocytic leukemia 30.2 CEBPA CREBBP FLT3 KIT RUNX1
4 acute respiratory distress syndrome 29.8 CEBPA FLT3 KIT NPM1
5 hemophagocytic lymphohistiocytosis 29.8 ABL1 FLT3 KIT NPM1 NUP98 PICALM
6 atypical chronic myeloid leukemia 12.4
7 cytogenetically normal acute myeloid leukemia 12.3
8 core binding factor acute myeloid leukemia 12.3
9 familial acute myeloid leukemia with mutated cebpa 12.2
10 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 12.1
11 philadelphia-negative chronic myeloid leukemia 12.0
12 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.0
13 acute myeloid leukemia with t(9;11)(p22;q23) 12.0
14 acute myeloid leukemia with t(8;16)(p11;p13) translocation 12.0
15 acute myeloid leukemia with t(6;9)(p23;q34) 12.0
16 acute myeloid leukemia with minimal differentiation 12.0
17 leukemia, chronic myeloid, somatic 11.9
18 cebpa-associated familial acute myeloid leukemia 11.9
19 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 11.9
20 inherited acute myeloid leukemia 11.9
21 leukemia 11.8
22 acute myeloid leukemia with recurrent genetic anomaly 11.8
23 unclassified acute myeloid leukemia 11.8
24 acute myeloid leukemia, flt3-related 11.8
25 acute myeloid leukemia, kit-related 11.8
26 acute myeloid leukemia, somatic dnmt3a-related 11.8
27 acute myeloid leukemia, susceptibility, gata2-related 11.8
28 npm1-related acute myeloid leukemia 11.8
29 acute myeloid leukemia and myelodysplastic syndromes related to radiation 11.8
30 acute myeloid leukemia with cebpa somatic mutations 11.8
31 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 11.8
32 acute myeloid leukemia with npm1 somatic mutations 11.8
33 acute myeloid leukemia with 11q23 abnormalities 11.8
34 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.8
35 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 11.8
36 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 11.8
37 leukemia, acute promyelocytic, somatic 11.7
38 acute erythroid leukemia 11.6
39 myelodysplastic syndrome 11.6
40 acute myeloblastic leukemia with maturation 11.5
41 mast-cell leukemia 11.4
42 megakaryocytic leukemia 11.3
43 myeloid sarcoma 11.3
44 essential thrombocythemia 11.2
45 myeloproliferative neoplasm 11.2
46 acute monocytic leukemia 11.2
47 pulmonary alveolar proteinosis 11.2
48 monocytic leukemia 11.2
49 chronic myelocytic leukemia 11.2
50 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 11.0

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.43 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.43 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.43 ABL1 FLT3 KIT
4 Increased shRNA abundance GR00327-A 9.1 CEBPA ERG FLT3 MCL1 MYH11 PTPN11

MGI Mouse Phenotypes related to Myeloid Leukemia:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 KIT LIF MCL1 MYH11 NPM1 PICALM
2 growth/size/body region MP:0005378 10.37 ABL1 CBFB CEBPA CREBBP ERG FLT3
3 hematopoietic system MP:0005397 10.35 ABL1 CBFB CCNA1 CEBPA CREBBP ERG
4 cardiovascular system MP:0005385 10.34 RUNX1 RUNX1T1 ABL1 CBFB CEBPA CREBBP
5 immune system MP:0005387 10.31 KIT LIF MCL1 NPM1 NUP98 PICALM
6 embryo MP:0005380 10.3 KIT LIF MCL1 NPM1 NUP98 ABL1
7 endocrine/exocrine gland MP:0005379 10.29 ABL1 CBFB CCNA1 CEBPA CREBBP ERG
8 mortality/aging MP:0010768 10.25 ABL1 CBFB CCNA1 CEBPA CREBBP ERG
9 homeostasis/metabolism MP:0005376 10.23 LIF MYH11 PICALM PTPN11 RUNX1 ABL1
10 digestive/alimentary MP:0005381 10.19 ABL1 CBFB CEBPA CREBBP KIT LIF
11 integument MP:0010771 10.18 CBFB CEBPA CREBBP KIT LIF MCL1
12 liver/biliary system MP:0005370 10.07 RUNX1 ABL1 CBFB CEBPA CREBBP KIT
13 neoplasm MP:0002006 9.81 CBFB CEBPA CREBBP ERG FLT3 KIT
14 muscle MP:0005369 9.8 ABL1 CEBPA CREBBP KIT LIF MYH11
15 normal MP:0002873 9.65 ABL1 CBFB CEBPA CREBBP ERG KIT
16 respiratory system MP:0005388 9.32 ABL1 CBFB CEBPA CREBBP ERG KIT

Drugs & Therapeutics for Myeloid Leukemia

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bosulif 17 46 BOSUTINIB MONOHYDRATE Pfizer Approved September 2012
2
Gleevec 17 46 IMATINIB MESYLATE Novartis Approved May 2001
3
Iclusig 17 46 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals Approved December 2012
4
Lynparza 17 46 OLAPARIB AstraZeneca Approved December 2014
5
Mylotarg 17 46 GEMTUZUMAB OZOGAMICIN Wyeth Approved May 2000
6
Sprycel 17 46 DASATINIB Bristol-Myers Squibb Approved June 2006
7
Synribo 17 46 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical Approved October 2012
8
Tasigna 17 46 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis Approved October 2007

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 677)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
3
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
4
Daunorubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 20830-81-3 30323
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Idarubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58957-92-9 42890
7
Topotecan Approved, Investigational Phase 4,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
8
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
9
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
10
Amsacrine Approved Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
12
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
13
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
14
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
15
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
16
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
18
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
19
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
20
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1 191732-72-6 216326
21
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
22
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
23
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
24
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1327-53-3 518740
25
Nicotine Approved Phase 4 54-11-5 942 89594
26
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
27
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
28
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
29
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
30
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 302-79-4 5538
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
32
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
33
Vitamin C Approved, Nutraceutical Phase 4,Phase 2,Phase 1 50-81-7 5785 54670067
34
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
35 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
36
Aclarubicin Investigational Phase 4,Phase 2,Phase 1 57576-44-0 451415
37
Histamine Phosphate Phase 4,Phase 3,Phase 1,Phase 2 51-74-1 65513
38 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
39 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1 123596
40 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1
41 interferons Phase 4,Phase 3,Phase 2,Phase 1
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
43 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
45 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
46 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
47 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Gemtuzumab Phase 4,Phase 2,Phase 3,Phase 1
50 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2985)
id Name Status NCT ID Phase
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4
3 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4
4 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4
5 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
6 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
7 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4
8 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4
9 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4
10 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4
11 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4
12 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4
13 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4
14 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4
15 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4
16 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4
17 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4
18 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4
19 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4
20 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4
21 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4
22 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4
23 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4
24 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4
25 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4
26 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4
27 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4
28 Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care Completed NCT00161668 Phase 4
29 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4
30 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4
31 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4
32 A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome Completed NCT01041846 Phase 4
33 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
34 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
35 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4
36 Treatment of Acute Myeloblastic Leukemia in Younger Patients Completed NCT00390715 Phase 4
37 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4
38 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4
39 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4
40 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4
41 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Recruiting NCT02228382 Phase 4
42 Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML Recruiting NCT02474290 Phase 4
43 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4
44 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4
45 Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib Recruiting NCT02689440 Phase 4
46 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Recruiting NCT02027064 Phase 4
47 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4
48 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4
49 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4
50 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4

Search NIH Clinical Center for Myeloid Leukemia

Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

id Genetic test Affiliating Genes
1 Myeloid Leukemia 29

Anatomical Context for Myeloid Leukemia

MalaCards organs/tissues related to Myeloid Leukemia:

39
Myeloid, Bone, Bone Marrow, T Cells, Monocytes, Endothelial, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloid Leukemia:

18
Myeloid Tissue

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 5726)
id Title Authors Year
1
Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome. ( 28509586 )
2017
2
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. ( 28056203 )
2017
3
Erratum to: "Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of in Vivo T Cell Depletion" [Biol Blood Marrow Transplant 2015;21:1754-1760]. ( 28068509 )
2017
4
BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation. ( 28484156 )
2017
5
Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. ( 28069548 )
2017
6
Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance. ( 27825294 )
2017
7
Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. ( 28054140 )
2017
8
ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. ( 28112576 )
2017
9
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. ( 28383355 )
2017
10
Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. ( 28058493 )
2017
11
A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. ( 27770540 )
2017
12
Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. ( 28184925 )
2017
13
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. ( 28088653 )
2017
14
Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia. ( 28322996 )
2017
15
Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT. ( 28052366 )
2017
16
Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50A years of age: a systematic review and meta-analysis. ( 28470473 )
2017
17
The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. ( 27875938 )
2017
18
Response: Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. ( 28085495 )
2017
19
Precision oncology for acute myeloid leukemia using a knowledge bank approach. ( 28092685 )
2017
20
ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia. ( 27640403 )
2017
21
Clinical Outcome of Autologous Hematopoietic Cell Transplantation (HCT) in Adult Patients with Acute Myeloid Leukemia: Who May Benefit From Autologous HCT? ( 28089879 )
2017
22
Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG). ( 28090090 )
2017
23
CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics. ( 27305704 )
2017
24
Cytogenetic and Cytogenomic Microarray Characterization of Chromothripsis in Chromosome 8 Affecting MOZ/NCOA2 (TIF2), FGFR1, RUNX1T1, and RUNX1 in a Pediatric Acute Myeloid Leukemia. ( 28085746 )
2017
25
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. ( 28514758 )
2017
26
Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia. ( 27577964 )
2017
27
Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment. ( 28091414 )
2017
28
Myelodysplasia and acute myeloid leukemia fifteen years after high-dose cyclophosphamide in a child with severe aplastic anemia. ( 28270348 )
2017
29
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. ( 28159598 )
2017
30
Myeloid leukemia factor-1 is a novel modulator of neonatal rat cardiomyocyte proliferation. ( 28087342 )
2017
31
Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. ( 28085518 )
2017
32
MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. ( 28084850 )
2017
33
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. ( 28076884 )
2017
34
T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide results in outcomes similar to traditionally matched donors in active disease acute myeloid leukemia. ( 28087457 )
2017
35
Acute myeloid leukemia in Baraitser-Winter cerebrofrontofacial syndrome. ( 27868373 )
2017
36
MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia. ( 27738758 )
2017
37
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? ( 27915304 )
2017
38
Detection of a clone-specific GATA1 mutation to monitor treatment response and involvement of a monozygotic twin in myeloid leukemia of Down syndrome. ( 28074551 )
2017
39
MN1 and PTEN gene expression in acute myeloid leukemia. ( 27983532 )
2016
40
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. ( 28008177 )
2016
41
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. ( 26775260 )
2016
42
The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia. ( 26376588 )
2016
43
The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia. ( 26820131 )
2016
44
A Rare Case of Acute Myeloid Leukemia with a t(2;3) Chromosomal Translocation Characterized by Thrombophilia and Chemoresistance. ( 27334861 )
2016
45
Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a. ( 26728554 )
2016
46
Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells. ( 26938745 )
2016
47
Plasma cell leukemia mimicking acute myeloid leukemia. ( 28092885 )
2016
48
miR-34b Targets HSF1 to Suppress Cell Survival in Acute Myeloid Leukemia. ( 27296951 )
2016
49
Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells. ( 27211267 )
2016
50
Kallmann Syndrome and Chronic Myeloid Leukemia: A Rare Occurrence. ( 27766807 )
2016

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

Pathways related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1 12.33 CEBPA KIT RUNX1 RUNX1T1
2 12.15 ABL1 CCNA1 CEBPA CREBBP FLT3 KIT
3
Show member pathways
11.99 CCNA1 CEBPA FLT3 KIT RUNX1 RUNX1T1
4
Show member pathways
11.94 CREBBP LIF MCL1 PTPN11
5 11.82 ABL1 FLT3 KIT NPM1
6
Show member pathways
11.67 CREBBP KIT NPM1
7
Show member pathways
11.62 CREBBP MCL1 PTPN11
8 11.53 CEBPA CREBBP MCL1
9 11.48 CCNA1 CEBPA ERG FLT3 MEIS1 MLF1
10 11.45 CREBBP MCL1 NPM1
11 11.45 CCNA1 CEBPA CREBBP KIT
12 11.36 ABL1 CEBPA CREBBP
13 10.84 CREBBP FLT3 MCL1
14 10.43 CBFB RUNX1

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.65 ABL1 CBFB CCNA1 CEBPA CREBBP MCL1
2 nucleus GO:0005634 9.55 ABL1 CBFB CCNA1 CEBPA CREBBP ERG

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.92 CEBPA CREBBP NPM1 PICALM RUNX1
2 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.86 CBFB CEBPA CREBBP ERG LIF MEIS1
3 transcription from RNA polymerase II promoter GO:0006366 9.8 CBFB CEBPA ERG MEIS1 NPM1 RUNX1
4 positive regulation of MAPK cascade GO:0043410 9.67 FLT3 KIT LIF
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 FLT3 KIT LIF
6 definitive hemopoiesis GO:0060216 9.51 CBFB MEIS1
7 negative regulation of hormone secretion GO:0046888 9.48 LIF PTPN11
8 positive regulation of tyrosine phosphorylation of Stat1 protein GO:0042511 9.46 KIT LIF
9 regulation of response to DNA damage stimulus GO:2001020 9.43 ABL1 MCL1
10 Bergmann glial cell differentiation GO:0060020 9.4 ABL1 PTPN11
11 megakaryocyte development GO:0035855 9.33 KIT MEIS1 PTPN11
12 myeloid progenitor cell differentiation GO:0002318 9.13 FLT3 KIT MLF1
13 hemopoiesis GO:0030097 9.02 FLT3 KIT MEIS1 PICALM RUNX1

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 ABL1 CBFB CCNA1 CEBPA CREBBP ERG
2 transcription coactivator activity GO:0003713 9.26 CBFB CEBPA CREBBP NPM1

Sources for Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....